Press Release

Analysis of Ophthalmic Drugs Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to 2024

Ophthalmic

The “Ophthalmic Drugs Market” 2019 report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. Ophthalmic Drugs Market report also aims to provide useful and comprehensive insights into current market trends and future growth scenarios. Ophthalmic Drugs market report contains information like SWOT analysis, business highlights, strength, weakness, threats and opportunities of industry.

Top Manufacturers of Ophthalmic Drugs Market Are:

  • Aerie Pharmaceuticals Inc.
  • Allergan
  • Bausch Health Companies Inc.
  • Bayer AG
  • F. Hoffmann
  • La Roche Ltd
  • Hoya Corporation
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co. Ltd

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14099187

    Market Overview:

  • The major factors attributed to the growth of the ophthalmic drugs market include the increasing incidence and prevalence of eye-related disorders, rising R&D activities pertaining to the development of novel drugs, and increasing focus on developing combination therapies.
  • The increasing prevalence of eye diseases is increasing the demand for ophthalmic drugs, globally. In many developed and developing countries, eye conditions have emerged as potential threats to the status of sight of their populations. The increase in the prevalence of diabetes in various countries has caused diabetic retinopathy to be added to the priority list. Glaucoma, an eye disease known for centuries, remains on the public health agenda due to difficulties in its early diagnosis and frequent necessity of life-long treatment. According to the WHO, in 2018, it was estimated that approximately 1.3 billion people were living with some form of vision impairment, 188.5 million people had a mild vision impairment, 217 million had moderate to severe vision impairment, and 36 million people are blind. Globally, the leading causes of vision impairment are uncorrected refractive errors and cataracts, and the majority of people with vision impairment are over the age of 50 years. According to the WHO, chronic eye diseases are the number one cause of vision loss, with the top two causes being unoperated cataracts and uncorrected refractive errors. The former is the leading cause in countries with low- or middle-incomes. More than 80% of the vision impairments are curable or preventable, which means that these drugs are required for the management of the diseases. Hence, the rising incidence of eye-related disorders is projecting a great impact on the growth of market studied.<

    Scope of the Report:

  • As per the , ophthalmic drugs are the drugs used for treating glaucoma, cataracts, diabetic retinopathy, and other ophthalmic disorders. An increasing prevalence of eye disorders and increasing R&D on the development of novel drugs are the major factors driving growth in the global ophthalmic drugs market. The market is segmented by drug class, product type, and geography.

    Ophthalmic Drugs Market Report Answers the Following Questions:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Ophthalmic Drugs market?
    • What are the key market trends impacting the growth of the global Ophthalmic Drugs market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Ophthalmic Drugs market?
    • What are the market opportunities and threats faced by the vendors in the global Ophthalmic Drugs market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Ophthalmic Drugs market?

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14099187

    Key Market Trends:

    The Dry Eye Segment under Drug Class is Expected to Account for the Largest Market Share during the Forecast Period

    Dry eye disease (DED) is a multi-factorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to aging, and hence, it remains an under-researched condition in the low- and middle-income countries. The prevalence of DED can be as high as 30% of the total population. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the aging population and the adoption of modern lifestyle. Dry eye disease is a common ocular disorder in the elderly and a frequent cause of eye care visits among this age group. The total annual cost of dry eye drug to the US economy can be more than USD 55 billion. Thus, the development of new drug treatments for dry eye is essential for both the dry eye patients and the ophthalmic industry. Many drugs are in the pipeline for dry eye diseases. The increasing prevalence of DED, approval of drugs for its treatment, and government initiatives to eradicate it are the main factors spurring the growth of the market studied.

    The Asia-Pacific Segment is Expected to Account for the Fastest Growth Rate

    The ophthalmic drugs market is expanding and growing, globally. The market has been witnessing an especially exponential growth in the Asia-Pacific region. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the Clinical and Experimental Vision and Eye Research, India, 2018. Increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth. According to the National Health Policy (NHP), in India, glaucoma is the leading cause of irreversible blindness with at least 12 million people have affected and nearly 1.2 million people having blinded from the disease. More than 90% of the cases of glaucoma remain undiagnosed in the country.

    Moreover, the prevalence of glaucoma increases with age. Thus, the rising prevalence of glaucoma and an increase in healthcare expenditure are spurring the growth of the ophthalmic drugs market in India. Furthermore, the country’s government is also playing an important role, since the cost of glaucoma treatment in India is one of the lowest in the world.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Ophthalmic Drugs Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Ophthalmic Drugs .

    Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/14099187

    Report Objectives:

    • Analyzing the size of the Ophthalmic Drugs market on the basis of value and volume.
    • Accurately calculating the market segments, consumption, and other dynamic factors of different sections of the global Ophthalmic Drugs market.
    • Determining the key dynamics of the Ophthalmic Drugs market.
    • Highlighting significant trends of the Ophthalmic Drugs market in terms of manufacture, revenue, and sales.
    • Deeply summarizing top players of the Ophthalmic Drugs market and showing how they compete in the industry.
    • Studying industry processes and costs, product pricing, and various trends related to them.
    • Displaying the performance of different regions and countries in the global Ophthalmic Drugs market.

    Detailed TOC of Ophthalmic Drugs Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Increasing Incidence and Prevalence of Eye-related Disorders
    4.2.2 Rising R&D Pertaining to the Development of Novel Drugs
    4.2.3 Increasing Focus on Developing Combination Therapies
    4.3 Market Restraints
    4.3.1 Loss of Patent Protection for Popular Drugs
    4.3.2 Lack of Health Insurance in the Developing Countries
    4.4 Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug Class
    5.1.1 Anti-glaucoma Drug
    5.1.2 Dry eye Drug
    5.1.3 Ophthalmic Anti-allergy/Inflammatory
    5.1.4 Retinal Drug
    5.1.5 Anti-infective Drugs
    5.1.6 Other Drugs
    5.2 By Product Type
    5.2.1 OTC Drug
    5.2.2 Prescription Drug
    5.3 Geography
    5.3.1 North America
    5.3.1.1 US
    5.3.1.2 Canada
    5.3.1.3 Mexico
    5.3.2 Europe
    5.3.2.1 Germany
    5.3.2.2 UK
    5.3.2.3 France
    5.3.2.4 Italy
    5.3.2.5 Spain
    5.3.2.6 Rest of Europe
    5.3.3 Asia-Pacific
    5.3.3.1 China
    5.3.3.2 Japan
    5.3.3.3 India
    5.3.3.4 Australia
    5.3.3.5 South Korea
    5.3.3.6 Rest of Asia-Pacific
    5.3.4 Middle East & Africa
    5.3.4.1 GCC
    5.3.4.2 South Africa
    5.3.4.3 Rest of Middle East & Africa
    5.3.5 South America
    5.3.5.1 Brazil
    5.3.5.2 Argentina
    5.3.5.3 Rest of South America

    6 COMPETITIVE LANDSCAPE
    6.1 Company Profiles
    6.1.1 Aerie Pharmaceuticals Inc.
    6.1.2 Allergan
    6.1.3 Bausch Health Companies Inc.
    6.1.4 Bayer AG
    6.1.5 F. Hoffmann-La Roche Ltd
    6.1.6 Hoya Corporation
    6.1.7 Novartis AG
    6.1.8 Pfizer Inc.
    6.1.9 Regeneron Pharmaceuticals Inc.
    6.1.10 Santen Pharmaceutical Co. Ltd

    7 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Semiconductor Equipment Market 2019: Global Industry Trends, Future Growth, Regional Overview, Market Share, Size, Revenue, and Forecast Outlook till 2024

    Tourism Guidance Service Market 2019 Research by Business Opportunities, Top Manufacture, Industry Growth, Industry Share Report, Size, Regional Analysis and Global Forecast to 2024 | Industry Research Biz

    Global Menthol Market by 2024 Comprehensive Analysis by Top Players, Challenges, Driving Factors, Market Size, and Shares

    Pin Gauges Market 2019 | Global Industry Size, Share, Explosive Factors of Key Players, Future Trends and Industry Growth Rate Forecast to 2023

    Tags
  • Alfredoo Epps

    Alfredo Epps is a finance expert heading the petroleum column. He joined the group last year as an associate writer. But his thorough research skills and ability to seamlessly putting numerical data into words helped him get a senior position. Apart from a column head, Alfredo is a dancer and a violinist.

    Related Articles

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Close